Cue Biopharma Stock Forward View - Triple Exponential Smoothing
| CUE Stock | USD 0.34 0.02 6.25% |
Cue Stock outlook is based on your current time horizon. Investors can use this forecasting interface to forecast Cue Biopharma stock prices and determine the direction of Cue Biopharma's future trends based on various well-known forecasting models. We suggest always using this module together with an analysis of Cue Biopharma's historical fundamentals, such as revenue growth or operating cash flow patterns.
At the present time the rsi of Cue Biopharma's share price is below 20 suggesting that the stock is significantly oversold. The fundamental principle of the Relative Strength Index (RSI) is to quantify the velocity at which market participants are driving the price of a financial instrument upwards or downwards. Momentum 0
Sell Peaked
Oversold | Overbought |
EPS Estimate Next Quarter (0.1) | EPS Estimate Current Year (0.40) | EPS Estimate Next Year (0.47) | Wall Street Target Price 4 | EPS Estimate Current Quarter (0.09) |
Using Cue Biopharma hype-based prediction, you can estimate the value of Cue Biopharma from the perspective of Cue Biopharma response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Cue Biopharma using Cue Biopharma's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Cue using crowd psychology based on the activity and movement of Cue Biopharma's stock price.
Cue Biopharma Implied Volatility | 1.57 |
Cue Biopharma's implied volatility exposes the market's sentiment of Cue Biopharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Cue Biopharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Cue Biopharma stock will not fluctuate a lot when Cue Biopharma's options are near their expiration.
The Triple Exponential Smoothing forecasted value of Cue Biopharma on the next trading day is expected to be 0.35 with a mean absolute deviation of 0.02 and the sum of the absolute errors of 1.48. Cue Biopharma after-hype prediction price | USD 0.37 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Check out Historical Fundamental Analysis of Cue Biopharma to cross-verify your projections. Open Interest Against 2026-04-17 Cue Option Contracts
Although open interest is a measure utilized in the options markets, it could be used to forecast Cue Biopharma's spot prices because the number of available contracts in the market changes daily, and new contracts can be created or liquidated at will. Since open interest in Cue Biopharma's options reflects these daily shifts, investors could use the patterns of these changes to develop long and short-term trading strategies for Cue Biopharma stock based on available contracts left at the end of a trading day.
Please note that to derive more accurate forecasting about market movement from the current Cue Biopharma's open interest, investors have to compare it to Cue Biopharma's spot prices. As Ford's stock price increases, high open interest indicates that money is entering the market, and the market is strongly bullish. Conversely, if the price of Cue Biopharma is decreasing and there is high open interest, that is a sign that the bearish trend will continue, and investors may react by taking short positions in Cue. So, decreasing or low open interest during a bull market indicates that investors are becoming uncertain of the depth of the bullish trend, and a reversal in sentiment will likely follow.
Cue Biopharma Additional Predictive Modules
Most predictive techniques to examine Cue price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Cue using various technical indicators. When you analyze Cue charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Cue Biopharma Triple Exponential Smoothing Price Forecast For the 12th of February 2026
Given 90 days horizon, the Triple Exponential Smoothing forecasted value of Cue Biopharma on the next trading day is expected to be 0.35 with a mean absolute deviation of 0.02, mean absolute percentage error of 0, and the sum of the absolute errors of 1.48.Please note that although there have been many attempts to predict Cue Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cue Biopharma's next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Cue Biopharma Stock Forecast Pattern
| Backtest Cue Biopharma | Cue Biopharma Price Prediction | Research Analysis |
Cue Biopharma Forecasted Value
In the context of forecasting Cue Biopharma's Stock value on the next trading day, we examine the predictive performance of the model to find good statistically significant boundaries of downside and upside scenarios. Cue Biopharma's downside and upside margins for the forecasting period are 0 and 8.97, respectively. We have considered Cue Biopharma's daily market price to evaluate the above model's predictive performance. Remember, however, there is no scientific proof or empirical evidence that traditional linear or nonlinear forecasting models outperform artificial intelligence and frequency domain models to provide accurate forecasts consistently.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Triple Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Cue Biopharma stock data series using in forecasting. Note that when a statistical model is used to represent Cue Biopharma stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0027 |
| MAD | Mean absolute deviation | 0.0247 |
| MAPE | Mean absolute percentage error | 0.0653 |
| SAE | Sum of the absolute errors | 1.4829 |
Predictive Modules for Cue Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Cue Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cue Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cue Biopharma After-Hype Price Density Analysis
As far as predicting the price of Cue Biopharma at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Cue Biopharma or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Cue Biopharma, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Cue Biopharma Estimiated After-Hype Price Volatility
In the context of predicting Cue Biopharma's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Cue Biopharma's historical news coverage. Cue Biopharma's after-hype downside and upside margins for the prediction period are 0.02 and 9.00, respectively. We have considered Cue Biopharma's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models compare with traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Cue Biopharma is abnormally volatile at this time. Analysis and calculation of next after-hype price of Cue Biopharma is based on 3 months time horizon.
Cue Biopharma Stock Price Outlook Analysis
Have you ever been surprised when a price of a Company such as Cue Biopharma is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cue Biopharma backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Cue Biopharma, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.65 | 8.63 | 0.03 | 0.33 | 9 Events / Month | 6 Events / Month | In about 9 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | |
0.34 | 0.37 | 8.82 |
|
Cue Biopharma Hype Timeline
On the 11th of February 2026 Cue Biopharma is traded for 0.34. The entity has historical hype elasticity of 0.03, and average elasticity to hype of competition of 0.33. Cue is anticipated to increase in value after the next headline, with the price projected to jump to 0.37 or above. The average volatility of media hype impact on the company the price is over 100%. The price growth on the next news is projected to be 8.82%, whereas the daily expected return is currently at -0.65%. The volatility of related hype on Cue Biopharma is about 1698.82%, with the expected price after the next announcement by competition of 0.67. The company has Return on Asset of (0.6231) % which means that on every $100 spent on assets, it lost $0.6231. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (1.9519) %, meaning that it generated no profit with money invested by stockholders. Cue Biopharma's management efficiency ratios could be used to measure how well Cue Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -1.38. The current year's Return On Capital Employed is expected to grow to -2.45. At present, Cue Biopharma's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 974.7 K, whereas Non Currrent Assets Other are forecasted to decline to about 2.2 M. Considering the 90-day investment horizon the next anticipated press release will be in about 9 days. Check out Historical Fundamental Analysis of Cue Biopharma to cross-verify your projections.Cue Biopharma Related Hype Analysis
Having access to credible news sources related to Cue Biopharma's direct competition is more important than ever and may enhance your ability to predict Cue Biopharma's future price movements. Getting to know how Cue Biopharma's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Cue Biopharma may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| NRXP | NRX Pharmaceuticals | (0.13) | 9 per month | 0.00 | (0.09) | 8.06 | (8.24) | 21.29 | |
| OTLK | OUTLOOK THERAPEUTICS INC | 0.02 | 11 per month | 0.00 | (0.11) | 11.32 | (11.11) | 73.07 | |
| EQ | Equillium | (0.06) | 6 per month | 6.10 | 0.06 | 19.26 | (11.82) | 43.07 | |
| COEP | Coeptis Therapeutics | 0.39 | 6 per month | 0.00 | (0.05) | 7.91 | (6.83) | 31.89 | |
| SPRB | Spruce Biosciences Common | 5.11 | 5 per month | 0.00 | (0.07) | 9.21 | (9.96) | 27.07 | |
| IOBT | IO Biotech | (0.01) | 5 per month | 12.35 | 0 | 13.33 | (16.22) | 151.49 | |
| IPSC | Century Therapeutics | (0.12) | 10 per month | 5.39 | 0.23 | 14.71 | (10.94) | 59.27 | |
| MDCX | Medicus Pharma Ltd | 0.00 | 0 per month | 0.00 | (0.26) | 6.22 | (8.93) | 21.20 | |
| SNTI | Senti Biosciences | (0.04) | 9 per month | 0.00 | (0.14) | 7.73 | (8.89) | 53.50 | |
| BRNS | Barinthus Biotherapeutics plc | (0.08) | 6 per month | 0.00 | (0.17) | 5.71 | (7.79) | 24.01 |
Other Forecasting Options for Cue Biopharma
For every potential investor in Cue, whether a beginner or expert, Cue Biopharma's price movement is the inherent factor that sparks whether it is viable to invest in it or hold it better. Cue Stock price charts are filled with many 'noises.' These noises can hugely alter the decision one can make regarding investing in Cue. Basic forecasting techniques help filter out the noise by identifying Cue Biopharma's price trends.Cue Biopharma Related Equities
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Cue Biopharma stock to make a market-neutral strategy. Peer analysis of Cue Biopharma could also be used in its relative valuation, which is a method of valuing Cue Biopharma by comparing valuation metrics with similar companies.
| Risk & Return | Correlation |
Cue Biopharma Market Strength Events
Market strength indicators help investors to evaluate how Cue Biopharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cue Biopharma shares will generate the highest return on investment. By undertsting and applying Cue Biopharma stock market strength indicators, traders can identify Cue Biopharma entry and exit signals to maximize returns.
| Accumulation Distribution | 63886.25 | |||
| Daily Balance Of Power | 0.6667 | |||
| Rate Of Daily Change | 1.06 | |||
| Day Median Price | 0.35 | |||
| Day Typical Price | 0.34 | |||
| Price Action Indicator | 0.005 | |||
| Period Momentum Indicator | 0.02 |
Cue Biopharma Risk Indicators
The analysis of Cue Biopharma's basic risk indicators is one of the essential steps in accurately forecasting its future price. The process involves identifying the amount of risk involved in Cue Biopharma's investment and either accepting that risk or mitigating it. Along with some essential techniques for forecasting cue stock prices, we also provide a set of basic risk indicators that can assist in the individual investment decision or help in hedging the risk of your existing portfolios.
| Mean Deviation | 5.45 | |||
| Standard Deviation | 8.27 | |||
| Variance | 68.4 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Cue Biopharma
The number of cover stories for Cue Biopharma depends on current market conditions and Cue Biopharma's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Cue Biopharma is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Cue Biopharma's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Cue Biopharma Short Properties
Cue Biopharma's future price predictability will typically decrease when Cue Biopharma's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Cue Biopharma often depends not only on the future outlook of the potential Cue Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Cue Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 56.3 M | |
| Cash And Short Term Investments | 23.4 M |
Check out Historical Fundamental Analysis of Cue Biopharma to cross-verify your projections. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Cue diversify its offerings? Factors like these will boost the valuation of Cue Biopharma. Projected growth potential of Cue fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Cue Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (0.43) | Revenue Per Share | Quarterly Revenue Growth (0.36) | Return On Assets | Return On Equity |
Cue Biopharma's market price often diverges from its book value, the accounting figure shown on Cue's balance sheet. Smart investors calculate Cue Biopharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Cue Biopharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cue Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cue Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.